Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT05633264

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Conditions: Psoriasis

Sex: All

Enrollment: 300

Sponsor: Bristol-Myers Squibb

Location: Japan

Summary

The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.

Eligibility Criteria

Inclusion Criteria:Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMSExclusion Criteria:Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05633264). StuddyBuddy aggregates publicly available trial information.